Europe Life Sciences Weekly Signal #57: The Tenth Year Needs an Investment Case
The EU pharma package would make the standard tenth year of regulatory protection conditional. Its commercial value belongs in the investment case before trial and filing commitments are made.
A year of regulatory protection has no fixed commercial value. It may postpone generic or biosimilar competition. It may also overlap with patent protection and add little to an asset’s expected returns. Securing it can require investment years before either outcome is clear.
On 28 September, the Council of the EU adopted its first-reading position on the pharma package. The new rules are not yet in force: Parliament must still adopt the legislation, followed by publication in the Official Journal. Council announcement.
My take: commercial leaders need to help price the development choices that could earn that year. The asset plan should connect clinical evidence, filing readiness and future competitive exposure before the programme becomes expensive to change.
The signal: different routes to the tenth year
The current standard framework provides eight years of data protection followed by two years of market protection. The Council text would retain eight years of data protection and reduce baseline market protection to one year, with conditional extensions. EMA guidance, section 6.2.1, Council summary.
For medicines containing a new active substance, Article 84 provides three alternative combinations for the initial marketing-authorisation application:
| Route | What must be combined |
|---|---|
| Comparator + filing timing | Relevant, evidence-based comparator trials supporting the initial application, in accordance with EMA scientific advice; EU application first, or within 90 days of the first application outside the EU. |
| Comparator + trial footprint | The same comparator condition; efficacy trials used for authorisation conducted in more than one EU Member State. |
| Comparator exception | Justification that such comparator trials are not possible or appropriate; both the multi-state efficacy-trial and filing-timing conditions. |
A separate unmet-medical-need route exists, with further conditions for conditional authorisations. Meeting several of these alternatives would not add several extra years. Council-adopted directive, Article 84.
The distinction matters. Timely EU filing, paired with qualifying comparator trials, would be one route rather than a universal requirement. The comparator-and-footprint route creates a different set of commitments.
Applications submitted before 24 months after the directive enters into force would retain the existing protection provisions. That makes the expected application date central to planning. Article 221(5).
The investment question starts with the asset
Start with the programme needed to produce credible clinical evidence. Then identify the additional commitments required by a plausible protection route.
One route could require earlier EU dossier readiness. Another could require a different European efficacy-trial footprint. Each has its own costs, delivery risks and timing implications. Evidence generated to qualify may also strengthen the case for access, if it answers questions relevant to the intended treatment setting.
The valuation should show how much the extension changes expected competitive exposure. Patents, supplementary protection certificates, reimbursement timing and anticipated competition all affect the answer. Where other protection already covers the relevant period, the incremental commercial benefit may be limited.
Compare the risk-adjusted present value of that benefit with the added development costs and any delay. Include the probability of qualifying. Show which assumptions would reverse the decision.
This is where commercial leadership adds something concrete: connecting a future protection benefit to the evidence, timing and resources required today. A forecast becomes more useful when those dependencies are visible.
Three commitments before the next programme decision
Choose a route and cost it. Identify the applicable protection regime, the intended route and the evidence needed to support it. Put the resulting commitments into the asset investment case. A deliberate decision to forgo an extension can be sound if the additional investment would undermine the programme’s overall value.
Align the evidence questions early. Comparator planning should address regulatory and access needs. For products in scope, developers can request EMA scientific advice in parallel with an EU HTA joint scientific consultation, subject to selection. These processes have different remits; their advice cannot assure a favourable reimbursement outcome. EMA explanation of parallel consultation.
Make the filing dependency explicit. If the chosen route uses the 90-day condition, readiness must be anchored to the first marketing-authorisation application outside the EU. That clock concerns submission. Approval and national launch have their own timelines. The access decisions discussed in Signal #56 still need a separate plan.
AI could change the cost of earning the year
On 30 September, US HHS announced ARPA-H’s SURPASS programme, pursuing model-assisted trial design, continuous analysis and agentic trial operations. These are development objectives; the announcement does not establish reductions in trial cost or duration. HHS announcement.
For the investment case, the useful question is what measured improvement in cost, time or evidence quality would justify changing the programme. Regulatory acceptability belongs in that assessment. Proven improvements could alter the economics of a qualifying route; projected savings need evidence before entering the valuation.
What to watch?
Watch Parliament’s final adoption, the published legislation and the comparator guidance Article 84 requires EMA to establish. Those will sharpen eligibility and implementation planning. Council next steps, Article 84(4).
The decision worth preparing now is which route fits the asset, what it would cost and how much value it could create.
The tenth year needs an investment case before it becomes a forecast assumption.
